{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:51:33Z","timestamp":1793656293607,"version":"4.5.1"},"reference-count":82,"publisher":"Informa UK Limited","issue":"15","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,10,12]]},"DOI":"10.1080\/14656566.2024.2416924","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T11:25:42Z","timestamp":1728732342000},"page":"1983-1998","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"University of Toronto","place":["Toronto, Canada"]},{"name":"Mediprobe Research Inc","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avantika","family":"Mann","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Polla Ravi","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14988"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2019.1685493"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00660-1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012093.pub2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14346"},{"key":"e_1_3_5_8_1","unstructured":"United states-food and drug administration. JUBLIA (efinaconazole) topical solution [Internet]. 2020 [cited 2024 Jun 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203567s009lbl.pdf"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S69596"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1942421"},{"issue":"9","key":"e_1_3_5_12_1","first-page":"1010","article-title":"Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis","volume":"12","author":"Jarratt M","year":"2013","unstructured":"Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol. 2013;12(9):1010\u20131016.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5401"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1004"},{"issue":"11","key":"e_1_3_5_15_1","first-page":"1388","article-title":"Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails","volume":"13","author":"Sakamoto M","year":"2014","unstructured":"Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13(11):1388\u20131392.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00111-14"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.47.1417"},{"issue":"8","key":"e_1_3_5_18_1","first-page":"859","article-title":"The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy","volume":"14","author":"Gupta AK","year":"2015","unstructured":"Gupta AK, Pillai R. The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy. J Drugs Dermatol. 2015;14(8):859\u2013863.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"e_1_3_5_19_1","first-page":"34","article-title":"Penetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail Polish","volume":"7","author":"Zeichner JA","year":"2014","unstructured":"Zeichner JA, Stein Gold L, Korotzer A. Penetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail Polish. J Clin Aesthet Dermatol. 2014;7(9):34\u201336.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488369"},{"key":"e_1_3_5_21_1","unstructured":"Health Canada. Product monograph PrJUBLIA\u00ae efinaconazole topical solution 10% w\/w topical antifungal agent [Internet]. 2020 [cited 2024 Jun 24]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00054721.PDF"},{"key":"e_1_3_5_22_1","unstructured":"Center for Drug Evaluation and Research. Efinaconazole 10% solution pharmacology review [Internet]. 2020 [cited 2024 Jul 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/203567Orig1s000SumR.pdf"},{"key":"e_1_3_5_23_1","first-page":"20","article-title":"Efinaconazole 10% solution, a new topical treatment for onychomycosis","volume":"6","author":"Del Rosso JQ","year":"2013","unstructured":"Del Rosso JQ, Reece B, Smith K, et al. Efinaconazole 10% solution, a new topical treatment for onychomycosis. J Clin Aesthet Dermatol. 2013;6:20\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"e_1_3_5_24_1","first-page":"186","article-title":"Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study","volume":"12","author":"Tschen EH","year":"2013","unstructured":"Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol. 2013;12(2):186\u2013192.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.17966\/JMI.2021.26.2.35"},{"issue":"12","key":"e_1_3_5_26_1","first-page":"1269","article-title":"Long-term follow-up of onychomycosis patients treated with efinaconazole","volume":"16","author":"Pollak RA","year":"2017","unstructured":"Pollak RA, Ilie C. Long-term follow-up of onychomycosis patients treated with efinaconazole. J Drugs Dermatol. 2017;16(12):1269\u20131273.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14935"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.632"},{"key":"e_1_3_5_29_1","first-page":"815","article-title":"The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials","volume":"13","author":"Gupta AK","year":"2014","unstructured":"Gupta AK, Elewski BE, Sugarman JL, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13:815\u2013820.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514361"},{"issue":"10","key":"e_1_3_5_31_1","first-page":"1260","article-title":"Topical treatment of onychomycosis and clinically meaningful outcomes","volume":"15","author":"Gupta AK","year":"2016","unstructured":"Gupta AK, Korotzer A. Topical treatment of onychomycosis and clinically meaningful outcomes. J Drugs Dermatol. 2016;15(10):1260\u20131266.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_3_5_32_1","first-page":"58","article-title":"Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early","volume":"14","author":"Rich P","year":"2015","unstructured":"Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015;14(1):58\u201362.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_33_1","first-page":"175","article-title":"Is severity of disease a prognostic factor for cure following treatment of onychomycosis?","volume":"17","author":"Elewski BE","year":"2018","unstructured":"Elewski BE, Cantrell W, Lin T. Is severity of disease a prognostic factor for cure following treatment of onychomycosis? J Drugs Dermatol. 2018;17:175\u2013178.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"e_1_3_5_34_1","first-page":"694","article-title":"Managing assessments and expectations: patient responses following therapy with efinaconazole topical solution, 10%","volume":"14","author":"Bhatia N","year":"2015","unstructured":"Bhatia N. Managing assessments and expectations: patient responses following therapy with efinaconazole topical solution, 10%. J Drugs Dermatol. 2015;14(7):694\u2013698.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_3_5_35_1","first-page":"24","article-title":"Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis","volume":"8","author":"Rodriguez DA","year":"2015","unstructured":"Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthet Dermatol. 2015;8(6):24\u201329.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_36_1","first-page":"42","article-title":"Onychomycosis of toenails and post-hoc analyses with efinaconazole 10% solution once-daily treatment impact of disease severity and other concomitant associated factors on selection of therapy and therapeutic outcomes","volume":"9","author":"Del Rosso JQ","year":"2016","unstructured":"Del Rosso JQ. Onychomycosis of toenails and post-hoc analyses with efinaconazole 10% solution once-daily treatment impact of disease severity and other concomitant associated factors on selection of therapy and therapeutic outcomes. J Clin Aesthet Dermatol. 2016;9:42\u201347.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"e_1_3_5_37_1","first-page":"492","article-title":"Management of onychomycosis and co-existing tinea pedis","volume":"14","author":"Lipner SR","year":"2015","unstructured":"Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol. 2015;14(5):492\u2013494.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.7547\/14-088"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15739"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof8070742"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495042"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.19-00009"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16035"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpm.2019.12.015"},{"issue":"10","key":"e_1_3_5_45_1","first-page":"1186","article-title":"Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes","volume":"13","author":"Vlahovic TC","year":"2014","unstructured":"Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J Drugs Dermatol. 2014;13(10):1186\u20131190.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.23.027"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18638"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15973"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2018.1502451"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.04.032"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof9070710"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13708"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004105"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_131_17"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00761-x"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.20-00014"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-022-00636-7"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00059-22"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19217"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12168"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.40968"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02703-13"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00442-19"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.22-00021"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.7547\/22-132"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12870"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02056-12"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.23-00005"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.153010"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.40543"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16394"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof3020020"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13550"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-020-00434-z"},{"key":"e_1_3_5_75_1","unstructured":"PR Newswire. Almirall and kaken pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole [Internet]. 2021 [cited 2024 Jun 25]. Available from: https:\/\/www.prnewswire.com\/de\/pressemitteilungen\/almirall-and-kaken-pharmaceutical-enter-into-a-license-and-distribution-agreement-for-european-rights-to-the-topical-formulation-of-efinaconazole-850637563.html"},{"key":"e_1_3_5_76_1","unstructured":"Almirall. Almirall and kaken pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole [Internet]. 2021 [cited 2024 Jun 25]. Available from: https:\/\/www.almirall.com\/newsroom\/news\/almirall-and-kaken-pharmaceutical-enter-into-a-license-and-distribution-agreement-for-european-rights-to-the-topical-formulation-of-efinaconazole"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.011"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1939011"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16241"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060671"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17241"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S246025"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12854"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.693522"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2416924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:45:05Z","timestamp":1740393905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2416924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":82,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,10,12]]}},"alternative-id":["10.1080\/14656566.2024.2416924"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2416924","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}